Dora Dias-Santagata

TL;DR: Detailed genetic and histological analysis of 37 patients with drug-resistant non–small cell lung cancers carrying EGFR mutations provides new insights into the shifting sands of drug resistance evolution in lung cancers and suggests that serial biopsies may be essential in the quest to reverse or even prevent the development ofdrug resistance.

TL;DR: Using high-throughput FISH analyses in both cell lines and in patients with lung cancer, the potential to prospectively identify treatment naive, patients with EGFR-mutant lung cancer who will benefit from initial combination therapy is highlighted.

TL;DR: It is found that EGFR-mediated MAPK pathway reactivation leads to resistance to vemurafenib in BRAF-mutant colorectal cancers and that combined RAF and EGFR inhibition can lead to sustainedMAPK pathway suppression and improved efficacy in vitro and in tumor xenografts.

TL;DR: Analysis of repeat biopsies from ALK-positive patients progressing on various ALK inhibitors finds that each ALK inhibitor is associated with a distinct spectrum of ALK resistance mutations and that the frequency of one mutation - ALK G1202R - increases significantly after treatment with second-generation agents.

TL;DR: In an analysis of frozen tissue specimens, IDH1 mutation was associated with highly elevated tissue levels of the enzymatic product 2-hydroxyglutarate, defining a specific metabolic abnormality in this largely incurable type of gastrointestinal cancer and present a potentially new target for therapy.